Targeting IL-4 for the Treatment of Atopic Dermatitis.
IL-4
IL-4 inhibitor
atopic dermatitis
dupilumab
pascolizumab
pitrakinra
Journal
ImmunoTargets and therapy
ISSN: 2253-1556
Titre abrégé: Immunotargets Ther
Pays: New Zealand
ID NLM: 101606565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
08
2020
accepted:
16
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
Identifiants
pubmed: 33062619
doi: 10.2147/ITT.S260370
pii: 260370
pmc: PMC7532907
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
151-156Informations de copyright
© 2020 Chiricozzi et al.
Déclaration de conflit d'intérêts
Andrea Chiricozzi served as advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme, and UCB-Pharma Ketty Peris reports grants and personal fees for advisory Board meeting from Almirall, AbbVie, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside of the submitted work. Giampiero Girolomoni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Celltrion, Eli-Lilly, Genzyme, Leo Pharma, Menlo therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz and UCB Pharma. The authors report no conflicts of interest for this work.
Références
J Immunol. 2003 Sep 15;171(6):3262-9
pubmed: 12960356
Clin Immunol. 2008 Mar;126(3):332-7
pubmed: 18166499
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
J Allergy Clin Immunol. 2001 Aug;108(2):269-74
pubmed: 11496245
J Allergy Clin Immunol. 2016 Aug;138(2):336-49
pubmed: 27497276
N Engl J Med. 2002 Oct 10;347(15):1151-60
pubmed: 12374875
J Immunol. 2010 Mar 15;184(6):3186-90
pubmed: 20147633
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467325
Sci Rep. 2019 May 23;9(1):7772
pubmed: 31123339
Biochem Biophys Res Commun. 2008 Nov 7;376(1):234-40
pubmed: 18774776
J Allergy Clin Immunol. 2007 Jul;120(1):150-5
pubmed: 17512043
J Allergy Clin Immunol. 2009 Oct;124(4):761-70.e1
pubmed: 19815118
Clin Exp Allergy. 2002 Aug;32(8):1236-42
pubmed: 12190665
J Allergy Clin Immunol. 2011 Apr;127(4):1006-13.e1-4
pubmed: 21236478
Mucosal Immunol. 2016 Nov;9(6):1407-1417
pubmed: 26883724
Int J Mol Sci. 2019 Aug 20;20(16):
pubmed: 31434203
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6880-4
pubmed: 2970644
J Invest Dermatol. 2009 Aug;129(8):1878-91
pubmed: 19357709
Int Rev Immunol. 2008;27(6):472-96
pubmed: 19065352
J Invest Dermatol. 2008 Sep;128(9):2248-58
pubmed: 18385759
Allergy. 2020 May;75(5):1188-1204
pubmed: 31838750
J Immunol. 1998 Nov 1;161(9):5027-38
pubmed: 9794440
Allergy. 2020 Jan;75(1):54-62
pubmed: 31230370
J Allergy Clin Immunol. 2006 Apr;117(4):836-41
pubmed: 16630942
J Invest Dermatol. 2008 May;128(5):1067-70
pubmed: 18408746
J Immunol. 1990 Dec 1;145(11):3796-806
pubmed: 2147202
J Invest Dermatol. 2001 May;116(5):658-63
pubmed: 11348452
Int Arch Allergy Immunol. 2016;170(2):122-31
pubmed: 27637004
Expert Opin Investig Drugs. 2020 Oct;29(10):1089-1098
pubmed: 32703039
J Clin Invest. 1999 Apr;103(8):1103-11
pubmed: 10207161
Eur J Immunol. 2001 Mar;31(3):812-22
pubmed: 11241286
Adv Exp Med Biol. 1994;365:211-5
pubmed: 7887305
J Clin Invest. 1997 Jun 15;99(12):3009-17
pubmed: 9185525
J Allergy Clin Immunol. 2017 Apr;139(4S):S65-S76
pubmed: 28390479
J Allergy Clin Immunol. 2020 May;145(5):1406-1415
pubmed: 31891686
Genomics. 1989 Jan;4(1):47-52
pubmed: 2563351
Sci Immunol. 2018 Jul 6;3(25):
pubmed: 29980619
J Allergy Clin Immunol. 2012 Dec;130(6):1344-54
pubmed: 22951056
Br J Dermatol. 2011 Mar;164(3):586-92
pubmed: 21039413
Int Immunol. 2004 Aug;16(8):1155-60
pubmed: 15226271
J Dermatolog Treat. 2019 Oct 28;:1-7
pubmed: 31647347
J Invest Dermatol. 2001 Oct;117(4):977-83
pubmed: 11676841
J Allergy Clin Immunol. 1983 Jan;71(1 Pt 1):47-56
pubmed: 6337197
Clin Exp Immunol. 2002 Oct;130(1):93-100
pubmed: 12296858
Lancet. 2020 Aug 1;396(10247):345-360
pubmed: 32738956
J Allergy Clin Immunol. 2015 Jul;136(1):104-115.e7
pubmed: 25748064
Exp Dermatol. 2019 Dec;28(12):1501-1504
pubmed: 31505056
Expert Rev Clin Immunol. 2016 Jul;12(7):787-96
pubmed: 26967382
Arch Dermatol Res. 2004 Apr;295(11):459-64
pubmed: 15014952
Cell. 2017 Sep 21;171(1):217-228.e13
pubmed: 28890086
J Invest Dermatol. 2014 May;134(5):1342-1350
pubmed: 24280725
J Allergy Clin Immunol. 2010 Mar;125(3):744-6, 746.e1-746.e2
pubmed: 20226306
J Immunol. 2006 Aug 15;177(4):2131-7
pubmed: 16887972
J Allergy Clin Immunol. 2017 Sep;140(3):633-643
pubmed: 28887947
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3406-11
pubmed: 10725381
J Invest Dermatol. 2013 Apr;133(4):973-9
pubmed: 23223131
Genome Res. 2012 May;22(5):850-9
pubmed: 22310478
Cytokine. 2003 Aug 21-Sep 7;23(4-5):126-32
pubmed: 12967648
J Clin Invest. 1999 Oct;104(7):829-35
pubmed: 10510320
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):319-327
pubmed: 31157635
Res Immunol. 1993 Oct;144(8):584-90
pubmed: 8303077
J Immunol. 1993 Jun 15;150(12):5436-44
pubmed: 8099936
Br J Dermatol. 2000 Aug;143(2):373-8
pubmed: 10951148
Curr Opin Investig Drugs. 2010 Nov;11(11):1286-94
pubmed: 21157648